Sun Pharma secures global ex-US, ex-China rights to PCSK9 cholesterol drug
Sun Pharma has licensed rights from LIB Therapeutics to manufacture and commercialise lerodalcibep outside the US and China, subject to regulatory approvals. The deal gives the company an entry into the estimated $3.7 billion PCSK9 cholesterol-treatment market.
The development
Sun Pharma secured exclusive rights to commercialise and manufacture lerodalcibep outside the US and China, targeting a $3.7 billion PCSK9 market. It will pursue regulatory approvals in territories where the cholesterol drug is not yet approved.
The numbers
- $3.7 billion
- September 21
- 38%
- $2.9 billion
- $7 billion
Why it matters to operators and investors
Sun Pharma gains a potential specialty-care growth lever in cholesterol management, but launch timing and revenue will depend on regulatory approvals across its licensed markets.
What to watch next
- Regulatory filing and approval timelines for lerodalcibep in key ex-US, ex-China territories.
- Published clinical data, label language and any evidence of differentiation on LDL-C lowering, dosing frequency, safety or adherence.
- Commercial terms disclosed by either company, including upfront payments, milestones, royalties and supply responsibilities.
- Reimbursement decisions and treatment-positioning guidelines for PCSK9 therapies in major markets.
- Competitive pricing and access moves by Repatha, Praluent, Leqvio and emerging oral lipid-lowering treatments.
The counter-case
The deal may be strategically narrower than the headline suggests: it excludes the US and China, while the remaining markets are fragmented, reimbursement-sensitive and expensive to launch in. Lerodalcibep still requires regulatory approvals, and even approval would not ensure uptake against entrenched PCSK9 rivals such as Repatha and Praluent, plus Novartis's inclisiran. Sun Pharma could face sizable medical-affairs, market-access and distribution investment before meaningful revenue, while undisclosed licensing economics may dilute returns. The cited $3.7 billion market opportunity is not necessarily addressable by Sun Pharma or indicative of near-term sales.